Shares of Athersys (ATHX) are skyrocketing today, up 19% in pre-market trading, after the clinical-stage biotech announced encouraging summary results from its exploratory …
Maxim’s healthcare analyst Jason Kolbert weighed in with a few insights on Athersys, Inc. (NASDAQ:ATHX), after the company announced interim results from its exploratory Phase 2 clinical study …
In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Athersys (NASDAQ:ATHX) and raised his price target …
In a research report issued Monday, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Athersys (NASDAQ:ATHX) with a price target of …
